Trial reportDrug design, development and therapy2024
Clinical Study of Flumazenil Antagonizing Remimazolam on Nausea and Vomiting After Gynecologic Day Surgery.
Trial report in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Beneficial Effects of Remimazolam Compared with Dexmedetomidine as an Adjuvant in Total Intravenous Anaesthesia with Propofol and Remifentanil: A Randomised Controlled Trial.Medicina (Kaunas, Lithuania) · 2026Trial
- Effects of remimazolam on postanesthetic shivering and related clinical responses in patients undergoing cesarean section.Frontiers in medicine · 2026Trial
- Effects of penehyclidine hydrochloride or droperidol combined with dexamethasone on preventing postoperative nausea and vomiting after remimazolam-alfentanil general anesthesia for gynecological day surgery.BMC anesthesiology · 2025Trial
- Efficacy of intraoperative low-dose remimazolam as a third antiemetic agent for preventing early postoperative nausea in high-risk patient: A Randomized controlled trial.BMC anesthesiology · 2025Trial
- Comparison of remimazolam and sevoflurane for general anesthesia during transcatheter aortic valve implantation: a randomized trial.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2025Trial
- Effects of Remimazolam-Propofol with Flumazenil Reversal on the Emergence Time and Hemodynamics of Patients Undergoing Laparoscopic Partial Hepatectomy: A Prospective Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- The Effects of Low-Dose Remimazolam Adjunct on Propofol-Remifentanil Anaesthesia in Day Case Gynaecological Surgery: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Postoperative nausea and vomiting: translating pathophysiological mechanisms into clinical management.Perioperative medicine (London, England) · 2025Review
- Does Propofol-based or Remimazolam-based Anesthesia Impact the Incidence of Postoperative Nausea and Vomiting When Used In Combination With Prophylactic Dexamethasone and Ondansetron?Anesthesia progress · 2025Article
- Stereotactic Functional Neurosurgery Combining Sedation and Awake Procedures Using Remimazolam Besylate and Flumazenil: A Technical Note.Neurologia medico-chirurgica · 2025Article
- Article
- Comparison of Postoperative Nausea and Vomiting Between Sedation with Remimazolam and Dexmedetomidine in Transcatheter Aortic Valve Replacement Patients: A Single-Center Retrospective Observational Study.Journal of clinical medicine · 2025Article
- Effects of Different Body Mass Indexes on the Induction Dose of Remimazolam in Patients Undergoing Gynaecological Day Surgery: A Propensity Score-Matched Study.Drug design, development and therapy · 2025Observational
- Research Progress on the Clinical Application of Remimazolam Outside the Operating Room: A Review of Pharmacological Characteristics, Clinical Effects, and Safety.Clinical pharmacology : advances and applications · 2025Review
- Article
- Comment on "The incidences of nausea and vomiting after general anesthesia with remimazolam versus sevoflurane: a prospective randomized controlled trial".Korean journal of anesthesiology · 2024Article
- Comparison of Hemodynamic Parameters Based on the Administration of Remimazolam or Sevoflurane in Patients under General Anesthesia in the Beach Chair Position: A Single-Blinded Randomized Controlled Trial.Journal of clinical medicine · 2024Article
- Clinical Study of Flumazenil Antagonizing Remimazolam on Nausea and Vomiting After Gynecologic Day Surgery [Letter].Drug design, development and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the effect of flumazenil antagonizing remimazolam on postoperative nausea and vomiting (PONV) after gynecologic day surgery. Patients and Methods: 141 cases of gynaecological daycase surgery patients in Weifang People's Hospital were selected, randomized into group F (flumazenil group, 71 cases) and group C (control group, 70 cases). Dexamethasone 5 mg, flurbiprofen axetil 50 mg, and droperidol 1 mg were given intravenously before induction of anesthesia in both groups. Anesthesia induction: Remimazolam 0.25mg / kg was injected within 1 minute. After the patient fell asleep, mivacurium chloride 0.2mg / kg was injected for 30 seconds and alfentanil 20ug / kg was injected for 30 seconds. Anesthesia maintenance: Remimazolam 1mg/kg/h and alfentanil 40ug/kg/h were continuously pumped by micro pump. Stopping the injection of remimazolam and alfentanil at the end of the operation. Flumazenil 0.2 mg was given to antagonize remimazolam in group F after 1 minute. Group C was given an equal volume of saline. The incidence of PONV in the postoperative PACU and over a 24-hour period, patient awakening time, and general patient information were recorded. Results: The incidence of PONV in both groups within 24 hours was 50.70% in group F was significantly higher than 32.86% in group C. The difference was statistically significant (P < 0.05). The incidence of PONV in the PACU was 5.6% in group F and 8.6% in group C. The difference was not statistically significant (p > 0.05). Conclusion: Flumazenil antagonism of remimazolam increases the incidence of PONV within 24 hours in gynecologic day surgery patients and has no significant effect on the incidence of PONV in the PACU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.